The American Medical Association, the American Osteopathic Association, and the Medical Society for the District of Columbia have filed suit against the FTC in an attempt to exclude physicians from its Red Flags Rule, which requires financial institutions and other creditors to develop and implement a written plan for spotting warning signs of identity theft.
The American Medical Association (AMA), the American Osteopathic Association, and the Medical Society for the District of Columbia have filed suit against the FTC in an attempt to exclude physicians from its Red Flags Rule, which requires financial institutions and other creditors to develop and implement a written plan for spotting warning signs of identity theft.
The FTC contends that the regulation applies to physician practices that act as creditors when they accept insurance and bill patients after services are provided or allow patients to set up payment plans after services have been rendered. The suit, filed in May, alleges that the FTC is exceeding its statutory authority and acting "arbitrarily and capriciously" in applying the rule to physicians.
According to the suit, the regulation is not applicable to physicians because they do not fit within the definition of "creditor" under the Fair and Accurate Credit Transactions Act. In addition, the suit claims that the Red Flags Rule would impose significant burdens on physicians, particularly sole practitioners and small groups, and duplicates privacy requirements under existing laws such as the Health Insurance Portability and Accountability Act. For these and other reasons, the plaintiffs are asking the US District Court for the District of Columbia to declare application of the Red Flags Rule to physicians unlawful.
AMA v FTC (DDC 2010). http://www.ama-assn.org/ama1/pub/upload/mm/395/red-flags-lawsuit.pdf. Accessed July 16, 2010.
Mosie Baby Kit receives class 2 FDA clearance for intravaginal insemination
December 6th 2023Discover how Mosie Baby's at-home insemination kit, the first FDA-cleared of its kind, empowers individuals facing infertility challenges with an effective, easy-to-use solution for intravaginal insemination.
Read More
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
How plasma biomarkers illuminate brain health in women with HIV
December 4th 2023Discoveries from a comprehensive study reveal specific plasma biomarkers that may serve as indicators of neurological well-being in individuals living with HIV, shedding light on potential links to Alzheimer's disease and emphasizing the importance of early detection for improved outcomes.
Read More